136 results on '"Psimenou, E"'
Search Results
2. Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance
3. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases
4. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis
5. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
6. Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause
7. Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
8. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients
9. AChR-and MuSK-positive myasthenia gravis: Double trouble
10. Combination Treatment With Plasmapheresis and Rituximab for Recurrent Focal Segmental Glomerulosclerosis After Renal Transplantation
11. Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis
12. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
13. Prevalence of erectile dysfunction in patients with end stage renal failure
14. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis
15. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis
16. PS1378 AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS
17. PS1392 CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD
18. PS1393 PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD)
19. Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression
20. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
21. Cardiac and renal complications of carfilzomib in patients with multiple myeloma
22. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens
23. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
24. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
25. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis
26. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis
27. RENAL AND HEMATOLOGIC OUTCOMES OF BORTEZOMIB-BASED TREATMENT IN PATIENTS WITH LIGHT CHAIN DEPOSITION DISEASE
28. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
29. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
30. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
31. SERUM LEVELS OF VON WILLEBRAND FACTOR (VWF) BUT NOT OF ADAMTS-13 PREDICT FOR EARLY DEATH IN PATIENTS WITH AL AMYLOIDOSIS, INDEPENDENTLY OF CARDIAC BIOMARKERS
32. OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES
33. AChR-myasthenia gravis switching to double-seropositive several years after the onset
34. Polyomavirus BK infection in Greek renal transplant recipients
35. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
36. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
37. Atrial fibrillation in chronic hemodialysis patients: Prevalence, types, predictors, and treatment practices in Greece
38. Combination Treatment With Plasmapheresis and Rituximab for Recurrent Focal Segmental Glomerulosclerosis After Renal Transplantation
39. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens
40. THE COMBINATION OF LENALIDOMIDE WITH LOW DOSE DEXAMETHASONE AND CYCLOPHOSPHAMIDE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH PRIMARY SYSTEMIC (AL) AMYLOIDOSIS: RESULTS OF A PHASE 1/2 STUDY
41. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: Dosing of lenalidomide according to renal function and effect on renal impairment
42. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: An eight year follow-Up
43. Plasma Exchange in 4 Renal Transplant Patients With Proteinuria: 4
44. Rapamycin for Focal Segmental Glomerulosclerosis: A Report of 3 Cases
45. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group
46. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
47. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
48. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: A retrospective follow-up study
49. Statins and progression of renal failure: is a reconsideration of clinical practice guidelines justified?
50. Membranous glomerulonephritis in chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.